Post COVID-19, mucormycosis occurred after the SARS-CoV-2 has rampaged the human population and is a scorching problem among the pandemic globally, particularly among Asian countries. Invasive mucormycosis has been extensively reported from mild to severe COVID -19 survivors. The robust predisposing factor seems to be uncontrolled diabetes mellitus, comorbidity and immunosuppression acquired through steroid therapy. The prime susceptive reason for the increase of mucormycosis cases is elevated iron levels in the serum of the COVID survivors. A panoramic understanding of the infection has been elucidated based on clinical manifestation, genetic and non- genetic mechanisms of steroid drug administration, biochemical pathways and immune modulated receptor associations. This review lime-lights and addresses the “What”, “Why”, “How” and “When” about the COVID-19 associated mucormycosis (CAM) in a comprehensive manner with a pure intention to bring about awareness to the common public as the cases are inevitably and exponentially increasing in India and global countries as well. The article also unearthed the pathogenesis of mucormycosis and its association with the COVID-19 sequela, the plausible routes of entry, diagnosis and counter remedies to keep the infection at bay. Cohorts of case reports were analysed to spotlight the link between the pandemic COVID-19 and the nightmare-mucormycosis.

COVID-19 之后，毛霉菌病发生在 SARS-CoV-2 肆虐人口之后，是全球大流行病中的一个棘手问题，尤其是在亚洲国家。从轻度到重度 COVID -19 幸存者，广泛报道了侵袭性毛霉菌病。强有力的诱发因素似乎是不受控制的糖尿病、合并症和通过类固醇治疗获得的免疫抑制。毛霉菌病病例增加的主要原因是 COVID 幸存者血清中铁水平升高。已经基于临床表现、类固醇药物给药的遗传和非遗传机制、生化途径和免疫调节受体关联阐明了对感染的全景理解。这篇评论重点关注并解决了“什么”、“为什么”、以全面的方式“如何”和“何时”了解与 COVID-19 相关的毛霉菌病 (CAM)，其纯粹的目的是提高公众的认识，因为印度和全球国家的病例不可避免地呈指数增长。该文章还揭示了毛霉菌病的发病机制及其与 COVID-19 后遗症的关联，以及防止感染的可能侵入途径、诊断和应对措施。对病例报告队列进行了分析，以突出大流行 COVID-19 与噩梦毛霉菌病之间的联系。该文章还揭示了毛霉菌病的发病机制及其与 COVID-19 后遗症的关联，以及防止感染的可能侵入途径、诊断和应对措施。对病例报告队列进行了分析，以突出大流行 COVID-19 与噩梦毛霉菌病之间的联系。该文章还揭示了毛霉菌病的发病机制及其与 COVID-19 后遗症的关联，以及防止感染的可能侵入途径、诊断和应对措施。对病例报告队列进行了分析，以突出大流行 COVID-19 与噩梦毛霉菌病之间的联系。